The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Accretive Health beat expectations on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share grew significantly.
Margins increased across the board.
Accretive Health logged revenue of $260.1 million. The nine analysts polled by S&P Capital IQ wanted to see a top line of $254.3 million on the same basis. GAAP reported sales were 53% higher than the prior-year quarter's $170.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.17. The 10 earnings estimates compiled by S&P Capital IQ anticipated $0.16 per share on the same basis. GAAP EPS of $0.13 for Q4 were 160% higher than the prior-year quarter's $0.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 25.2%, 270 basis points better than the prior-year quarter. Operating margin was 8.5%, 310 basis points better than the prior-year quarter. Net margin was 5.1%, 180 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $229.8 million. On the bottom line, the average EPS estimate is $0.06.
Next year's average estimate for revenue is $1.11 billion. The average EPS estimate is $0.64.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 34 members out of 43 rating the stock outperform, and nine members rating it underperform. Among 11 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), six give Accretive Health a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accretive Health is outperform, with an average price target of $28.75.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Accretive Health prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Accretive Health to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Accretive Health Inc. Shares Slumped
Accretive Health updates its ongoing financial restatement timeline to which investors responded with two emphatic thumbs down.
Accretive Health Names CFO
Sean F. Orr is a poach from the CFO's post at Maxum Petroleum.
3 Horrendous Health-Care Stocks This Week
The Fool looks at 3 horrendous health-care stocks from the past week.